Your session is about to expire
← Back to Search
Targeted Therapy for Brain Cancer
Study Summary
This trial looks at whether genetic testing can help guide treatment for brain cancer. Medications that target specific genes may stop the growth of tumor cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had chemotherapy in the last 14 days.I am not on any strong medication that affects liver enzyme levels.You can get an MRI with a special dye called contrast.My cancer has spread to my brain from another part of my body.I have not had surgery within the last 2 weeks.I meet the specific health requirements for the ABEMACICLIB trial arm.To join the ADAGRASIB (MRTX849) arm, you need to meet specific requirements related to your blood, heart health, medications, and medical history. If you are a woman able to have children, you also need to use contraception.I am not taking any medications that would interfere with ENTRECTINIB treatment.I haven't had cancer in the last 5 years, except for skin cancer.My cancer has spread to my brain recently or is getting worse.I am not currently receiving any cancer treatments.I am not on any strong CYP3A4 inhibitors.I have had a condition where my lymphocytes multiply unusually.I have a history of cancer.I don't have recent heart issues, uncontrolled diabetes, or high protein in my urine.I have tissue samples available from previous surgeries or biopsies for testing.My cancer has a specific change in NTRK, ROS1, KRAS G12C, CDK, or PI3K that can be treated.My cancer type has specific treatment history requirements.I am able to care for myself and perform daily activities.My organs are working well and my lab tests are within normal ranges.I have had radiation for symptom relief in my nervous system before joining.I have been on a stable dose of dexamethasone for at least 7 days.
- Group 1: Arm IV (KRAS G12C mutation)
- Group 2: Arm III (NTRK/ROS1 gene mutation)
- Group 3: Arm I (CDK gene mutation)
- Group 4: Arm II (PI3K gene mutation)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experimental trial a pioneering endeavor?
"Currently, there are 106 active clinical trials for the PI3K Inhibitor paxalisib across 1346 cities and 57 countries. This pharmacological agent was first trialled in 2009 by Eli Lilly & Co with 220 participants. 38 studies have been successfully completed since then, attaining Phase 1 drug approval status."
What medical applications is PI3K Inhibitor paxalisib typically employed for?
"Paxalisib, a PI3K inhibitor, is designed to combat solid tumors and malignant neoplasms in cases where surgical resection is not possible or when no known resistance mutations have been acquired."
What potential risks does the PI3K Inhibitor paxalisib pose to individuals using it?
"Our experts at Power gave the PI3K Inhibitor Paxalisib a rating of 2 on our safety scale. This is due to Phase 2 trial data, which implies that prior studies have provided evidence for its safety but not efficacy."
What is the participant quota for this research trial?
"This medical trial necessitates 150 qualified patients, who can be recruited from a variety of places such as the University of Chicago Comprehensive Cancer Center in Illinois or the University of Kansas Cancer Center-Overland Park located in Kansas."
Is enrollment open for this research endeavor?
"Affirmative, clinicaltrials.gov states that this medical trial is actively enrolling patients since it was first publicized on August 15th 2019. The last update to the study occured on June 3rd 2022 and seeks 150 participants across 100 different sites."
How many health facilities are currently participating in this trial?
"This clinical trial requires 100 participants and is currently recruiting from medical centres such as the University of Chicago Comprehensive Cancer Centre, the University of Kansas Cancer Center-Overland Park, and Genesee Cancer & Blood Disease Treatment Centre. Additional enrolment sites can be found around the world."
Have previous studies explored the efficacy of PI3K Inhibitor paxalisib?
"Research into the PI3K Inhibitor paxalisib began in 2009 and has since been tested 38 times, with 106 studies actively recruiting participants. If you require more information about these trials, call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) on weekdays between 9 AM to 5 PM Eastern Time or contact your personal physician. Most of these clinical experiments are occurring in Chicago, Illinois."
Share this study with friends
Copy Link
Messenger